We scan new podcasts and send you the top 5 insights daily.
Rare malignancies like upper tract urothelial carcinoma struggle to enroll sufficiently powered randomized trials, taking up to eight years to report overall survival. Instead of waiting for traditional phase III registrational designs, experts advocate conducting smaller, 100-patient non-traditional studies using ctDNA clearance as an early surrogate endpoint. This strategy enables rapid evaluation of novel antibody-drug conjugate and immunotherapy combinations to inform clinical care far sooner.
The prognostic value of a positive ctDNA test in urothelial cancer intensifies throughout the treatment journey. Failure to clear ctDNA after neoadjuvant therapy and then surgery is associated with a dramatically increasing hazard ratio for death, signaling profound treatment failure.
Data from trials like Niagara suggests a powerful new paradigm for assessing treatment success. Combining urine tumor DNA (uTDNA) for local disease and circulating tumor DNA (ctDNA) for systemic relapse offers a more dynamic view than traditional pathology and is poised to become the superior surrogate endpoint in bladder cancer trials.
The type of treatment inducing ctDNA clearance matters. Clearance from immunotherapy appears to be more permanent and strongly prognostic than clearance from chemotherapy, which can be transient. This suggests immunotherapy may achieve a more profound and lasting elimination of cancer cells versus cytotoxic agents.
Circulating tumor DNA (ctDNA) identifies post-surgery patients at high risk of relapse. By targeting adjuvant immunotherapy to only this ctDNA-positive group, previously negative clinical trials demonstrate a significant survival benefit. This approach spares low-risk, ctDNA-negative patients from unnecessary treatment and toxicity.
Circulating tumor DNA (ctDNA) provides more actionable risk stratification than pathologic stage in resected upper tract disease. Patients who test ctDNA negative exhibit a low 20% to 30% risk of recurrence, making active surveillance reasonable to avoid toxic, marginally effective adjuvant therapies. Conversely, ctDNA positivity behaves like occult metastatic disease with recurrence rates approaching 95%, prompting clinicians to bypass adjuvant platinum for full-dose enfortumab vedotin plus pembrolizumab.
Measuring circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) after treatment is a powerful predictor of recurrence. This biomarker could be used as a surrogate endpoint in clinical trials, allowing for accelerated drug approvals based on early data rather than waiting years for survival outcomes.
The INTERCEPT study found only 2% of ctDNA-positive colorectal cancer patients clear the marker without intervention. This stable, high-risk baseline allows small trials to use ctDNA clearance as a rapid endpoint, potentially accelerating the development of new adjuvant therapies.
In adjuvant bladder cancer trials, ctDNA status is both prognostic and predictive. Patients with positive ctDNA after surgery are at high risk of relapse but benefit from immune checkpoint inhibitors. Conversely, ctDNA-negative patients have a lower risk and derive no benefit, making ctDNA a critical tool to avoid unnecessary, toxic therapy.
Across multiple recent trials, a consistent finding is that if a bladder cancer patient's circulating tumor DNA (ctDNA) does not clear after treatment, it is an extremely poor prognostic sign. This strong signal suggests that these patients should likely be switched to a different therapeutic approach immediately.
Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) offer complementary information. Used together, they provide superior risk stratification. Patients negative on both tests have a >70% chance of a complete pathological response, while those positive on both have only a ~5% chance, demonstrating clear additive value.